9 April 2019 - Deborah Wilkes
Nestlé Health Science has announced a partnership with Amazentis, Novartis has spun off Alcon, and Daiichi-Sankyo has changed its chief executive officer.
Nestlé works with Amazentis
Nestlé Health Science has entered into a global strategic partnership with Amazentis to develop its new cellular nutrient Urolithin A.
Under the terms of the partnership, Nestlé Health Science is taking an equity stake in Amazentis and will receive global rights to use the company's patented Urolithin A technology for dietary supplements, select foods and beverages, and medical nutrition products.
Amazentis retains co-exclusive rights for online distribution of dietary supplements and select food products as well as global exclusive rights for distribution of certain other defined categories.
The two companies will also conduct a joint research programme to extend applications of Urolithin A into new consumer health and medical benefit areas.
Nestlé said the partnership supported its "pursuit of growth opportunities both in consumer healthcare and medical nutrition".
Novartis spins off Alcon
Novartis has completed the spin-off of Alcon into a separately-traded company with annual sales of around USD7.1 billion.
Alcon said it was the largest eyecare device company in the world. Its headquarters are in Geneva, Switzerland, and it has a presence in 74 countries.
Daiichi-Sankyo makes change at top
Daiichi-Sankyo has announced a change of chief executive officer to achieve "further growth of the company".
George Nakayama will step down as chief executive officer of the Japanese company but remain chairman. Nakayama will be replaced by president and chief operating officer Sunao Manabe who has been promoted to president and chief executive officer.
According to a recent Reuters report, Daiichi-Sankyo is exploring the sale of its OTC business (click here to read the News story).
Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE